Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Nashville, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Sept 2025
- Expected to end
- 5 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Montelukast Oral Granules
- Record updated
- 18 November 2024
- Why it stopped
- Unfunded
Who can take part
- Age
- 5 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age 5 to 17 years, inclusive
- Parental report of asthma diagnosis by a health care provider
- At least one previous wheezing episode treated with albuterol
- Moderate or severe acute asthma exacerbation measured using the validated AAIRS bedside asthma severity score
Who cannot take part
- Prior study enrollment
- Gastroesophageal reflux requiring acid-blocking medication; and
- Prior use of an LTRA (e.g., montelukast)
- Chronic lung disease other than asthma
- Acute or chronic liver disease
- Allergy to montelukast
- Tuberculosis
- History of prematurity less than 34 weeks gestational age
- Presence of tracheostomy
- Use of noninvasive ventilation at home
- Need for immediate airway intervention (e.g., endotracheal intubation or noninvasive ventilation)
- Pregnancy
Where in United States
- Vanderbilt Children's HospitalNashville, United States
About the trial
What the trial wants to find out
Objective: To determine the extent to which high-dose (30mg) oral montelukast, added to standard treatment in children with moderate and severe acute exacerbations improves outcomes.
Read full original descriptionShow less
Central Hypothesis: High-dose oral montelukast, added to standard treatment in children aged 5 to 17 years with moderate and severe acute asthma exacerbations, rapidly improves lung function, clinical severity, hospitalization rate and 72-hour symptom burden.
Secondary Hypotheses:
1. There are greater effects of high-dose oral montelukast on lung function and on the secondary outcomes in the presence of respiratory viral detection or leukotriene-mediated inflammation; and 2. There is an interaction between viral detection and urinary leukotriene 4 level with treatment-response.
Design: A two-arm, parallel randomized controlled trial of high-dose oral montelukast versus identical placebo, as add-on to standard treatment, in children aged 5 to 17 years with moderate and severe acute asthma exacerbations.
Intervention: High-dose oral montelukast added to standard treatment in comparison with standard treatment as the 2nd treatment-allocation arm.
Primary and Important Secondary Endpoints: For the Primary Aim, the primary outcome measure to be compared between arms will be change of %-predicted airway resistance by impulse oscillometry (IOS) at 5Hz (%R5) at 2 hours after treatment initiation. Secondary outcomes will include improvement of %-predicted FEV1 (%FEV1), clinical severity measured using the validated Acute Asthma Intensity Research Score (AAIRS), hospitalization rate, and 72 hour symptom burden using the Pediatric Asthma Caregiver Diary (PACD). For the Secondary Aim, the investigators will determine (1) The effects of high-dose oral montelukast on lung function and on our secondary outcomes in the presence of nasal viruses and of greater leukotriene-mediated inflammation; and (2) The degree of interaction between viral detection and urinary leukotriene E4 (LTE4) level with treatment-response.
Laboratory evaluations: The primary outcome (change of %R5) and select secondary outcomes (%FEV1, AAIRS, LTE4) will be measured before and again at 2 hours after treatment initiation. The other secondary outcomes will be measured at the time of hospitalization decision-making by the clinical team (hospitalization rate) or at 72-hours after treatment initiation (PACD).
The 2 groups in the trial
- High-dose Montelukast Oral GranulesTreatment being tested
30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
Treatment: Montelukast Oral Granules
- PlaceboPlacebo, for comparison
Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
Treatment: Montelukast Oral Granules
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 November 2024